FRACTYL HEALTH, INC. - 8-K Filing
Fractyl Health announces 45% workforce reduction and discontinuation of Rejuva gene therapy program to focus on Revita® lead candidate. (Items: 2.05 Costs Associated with Exit or Disposal Activities, 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Offi, 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $GUTS